Empagliflozin Improves HbA1c in Young People With T2DM
TUESDAY, March 21, 2023 -- For young people, empagliflozin is associated with improvement in glycated hemoglobin (HbA1c), according to a study published in the March issue of The Lancet Diabetes& Endocrinology.
Lori M. Laffel, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 21, 2023 Category: Pharmaceuticals Source Type: news
Jardiance Under Review for CKD; Frailty in Obesity; DIY Semaglutide?
(MedPage Today) -- The FDA is reviewing a potential new indication for empagliflozin (Jardiance) for risk reduction of kidney disease progression and cardiovascular death in adults with chronic kidney disease (CKD) based on the EMPA-KIDNEY phase... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - January 24, 2023 Category: Endocrinology Source Type: news
Eli Lilly ’ s Alzheimer ’s Drug Donanemab Fails to Get Early FDA Approval
Eli Lilly & Co.’s bid for accelerated approval of its Alzheimer’s therapy donanemab was rejected by U.S. regulators, an unexpected setback for the drugmaker.
The Food and Drug Administration sent the company a complete response letter saying it would not give the early approval for the drug because not enough patients on the trial had received it for a full 12 months, Lilly said Thursday in a statement.
The agency wanted Lilly to provide safety data on at least 100 patients who had been on the drug for a year. Lilly’s application for accelerated approval was based on a relatively small mid-stage trial...
Source: TIME: Health - January 20, 2023 Category: Consumer Health News Authors: Robert Langreth and Nacha Cattan/Bloomberg Tags: Uncategorized bloomberg wire Drugs Source Type: news
The Year SGLT2 Inhibitors Became Full-Fledged Heart Failure Drugs
(MedPage Today) -- Earlier this year, empagliflozin (Jardiance) won FDA approval for a broader indication in heart failure across the spectrum of ejection fraction. As part of our review of the year's top stories, we follow up on what has happened... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - December 27, 2022 Category: Urology & Nephrology Source Type: news
Black HFrEF Patients Fare Better With Empagliflozin Black HFrEF Patients Fare Better With Empagliflozin
Empagliflozin trial data from patients with heart failure with reduced ejection fraction signal more benefit in Black compared with White patients.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2022 Category: Consumer Health News Tags: Cardiology News Source Type: news
Torrent Pharmaceuticals partner with Boehringer Ingelheim to co-market diabetes, cardiovascular medicines
Both companies entered into partnership for the sales and co-marketing of Empagliflozin and its combinations including Cospiaq (Empagliflozin), Cospiaq MetTM (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin) in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 14, 2022 Category: Pharmaceuticals Source Type: news
Highlights in Diabetes and Metabolism From ASN 2022 Highlights in Diabetes and Metabolism From ASN 2022
From ASN 2022, Dr Carol Wysham highlights data on glucose-lowering drugs in patients with T2D, including empagliflozin and semaglutide, and a link between cognitive disorders and albuminuria.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD EMPA-Kidney Seals SGLT2 Inhibitors as'Foundational' for CKD
Empagliflozin ' s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.Medscape Medical News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - November 22, 2022 Category: Respiratory Medicine Tags: Nephrology News Source Type: news
ASN: Empagliflozin Cuts Risk for Progression in CKD
WEDNESDAY, Nov. 9, 2022 -- For patients with chronic kidney disease at risk for progression, the risk for progression of kidney disease or death from cardiovascular causes is reduced with empagliflozin treatment, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 9, 2022 Category: Pharmaceuticals Source Type: news
Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - November 4, 2022 Category: Internal Medicine Tags: Nephrology News Source Type: news
Empagliflozin Protects At-Risk Patients From CKD Progression
(MedPage Today) -- Empagliflozin (Jardiance) reduced the risks of chronic kidney disease (CKD) progression and cardiovascular-related deaths in high-risk patients compared with placebo, the phase III EMPA-KIDNEY trial showed.
Over a median 2-year... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - November 4, 2022 Category: Urology & Nephrology Source Type: news
SGLT2 Inhibitor Role for Isolated Kidney Disease SGLT2 Inhibitor Role for Isolated Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 4, 2022 Category: Consumer Health News Tags: Nephrology News Source Type: news
EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease EMPA-Kidney Moves the Needle for SGLT2 Inhibitors in Kidney Disease
Empagliflozin significantly cut progression of chronic kidney disease in a pivotal trial that included people without diabetes or heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 4, 2022 Category: Cardiology Tags: Nephrology News Source Type: news
Serum Uric Acid Lowering With Empagliflozin in HFrEF Serum Uric Acid Lowering With Empagliflozin in HFrEF
Lowering of serum uric acid may be an added benefit of SGLT-2 inhibitors. Might it improve outcomes in patients with heart failure with reduced ejection fraction?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 26, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Empagliflozin and Elderly Patients With HFpEF Empagliflozin and Elderly Patients With HFpEF
Do elderly patients with HFpEF benefit as much as younger patients from treatment with an SGLT2 inhibitor? A new study demonstrates its efficacy across all age groups.Journal of the American College of Cardiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 17, 2022 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
